Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by mdjbrownon Oct 30, 2021 9:58am
108 Views
Post# 34067630

RE:International growth.

RE:International growth.Agree 100% alleyesonme.  This one certainly isnt a sprint, but more a methodical controlled jog to the finish line

With gradual increases in revenue the last 2 quarters, I expect another increase in over all sales as Medipharm products reach further corners of the world.

As you mention, positive results from trials could certainly add a lot of traction.

Germany politically changing their stance could open up more European doors for Medipharm as well.

Controlling their cash burn is also obviously paramount.

I find it very interesting that the official announcement of the CEO will coincide with the Q3 release timeline.  Hopefully they are planning to announce some unexpected fireworks in conjunction with Mr. Howcroft's joining the team, as that might be what it will take to put LABS back on the markets radar once again.

No reason this cant push upward to at least the exersize price of the warrants in the next quarter or so with good news, but I guess we will soon find out in 2 weeks time


<< Previous
Bullboard Posts
Next >>